We are live on ! Find out more
UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Portfolio holdings

AUM $863M
1-Year Est. Return 30.35%
This Fund
S&P 500
This Quarter Est. Return
+18.86%
1 Year Est. Return
+30.35%
3 Year Est. Return
+68.34%
5 Year Est. Return
+24.17%
10 Year Est. Return
AUM
$130M
AUM Growth
-$40.1M
Cap. Flow
-$59.1M
Cap. Flow %
-45.34%
Top 10 Hldgs %
99.1%
Holding
26
New
5
Increased
1
Reduced
3
Closed
8

Sector Composition

Rank Sector Weight
1 Healthcare 66.82%
2 Technology 4.74%
3 Energy 0.46%
4 Real Estate 0.03%
5 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACCD
26
DELISTED
Accolade Inc
ACCD
-1,191,326
Closed -$54M

Similar funds

University of Texas/Texas AM Investment Management Co (UTIMCO)'s Q2 2021 Portfolio in Review

As of Q2 2021, University of Texas/Texas AM Investment Management Co (UTIMCO) held 26 positions worth $130M, down 24% from $170M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

University of Texas/Texas AM Investment Management Co (UTIMCO) withdrew a net $59.1M in Q2 2021, closing 8 positions and reducing 3 holdings. Its most notable exit was Accolade Inc, an estimated $54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 55% a quarter earlier, followed by Technology and Energy.

Against the trend, University of Texas/Texas AM Investment Management Co (UTIMCO) opened a new position in Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant worth $20M.

  • University of Texas/Texas AM Investment Management Co (UTIMCO)'s largest Q2 2021 buy was Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant: 2,000,000 shares worth $20M.
  • University of Texas/Texas AM Investment Management Co (UTIMCO) added most to Beam Therapeutics in Q2 2021, an estimated $80 increase.
  • University of Texas/Texas AM Investment Management Co (UTIMCO)'s biggest Q2 2021 reduction was Taysha Gene Therapies, cutting an estimated $18.2M.
  • University of Texas/Texas AM Investment Management Co (UTIMCO) fully exited Accolade Inc in Q2 2021, selling an estimated $54M.
  • University of Texas/Texas AM Investment Management Co (UTIMCO)'s ten largest holdings make up 99% of its $130M portfolio in Q2 2021.
  • University of Texas/Texas AM Investment Management Co (UTIMCO) opened 5 new positions and closed 8 in Q2 2021.
  • University of Texas/Texas AM Investment Management Co (UTIMCO)'s portfolio value fell 24% quarter-over-quarter to $130M.

Based on University of Texas/Texas AM Investment Management Co (UTIMCO)'s 13F filing for Q2 2021, filed 6 Aug 2021.